Cargando…
Results of switchback from ranibizumab to aflibercept in patients with exudative age-related macular degeneration
PURPOSE: Intravitreal injection of anti-VEGF drugs has become standard therapy for patients with exudative age-related macular degeneration (AMD). However, some patients do not exhibit sufficient response to the drugs for suppression of choroidal neovascularization activity. We investigated the effi...
Autores principales: | Koike, Naoko, Otsuji, Tsuyoshi, Tsumura, Akiko, Miki, Katsuaki, Sakai, Yukio, Nishimura, Tetsuya, Takahashi, Kanji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6643053/ https://www.ncbi.nlm.nih.gov/pubmed/31409963 http://dx.doi.org/10.2147/OPTH.S206910 |
Ejemplares similares
-
Initial non-responders to ranibizumab in the treatment of age-related macular degeneration (AMD)
por: Otsuji, Tsuyoshi, et al.
Publicado: (2013) -
Three-year results of a modified photodynamic therapy procedure (Ironing PDT) for age-related macular degeneration patients with large lesions
por: Otsuji, Tsuyoshi, et al.
Publicado: (2016) -
Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab
por: Hamid, Mohamed A., et al.
Publicado: (2021) -
Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration
por: Barthelmes, Daniel, et al.
Publicado: (2016) -
AFLIBERCEPT AFTER RANIBIZUMAB INTRAVITREAL INJECTIONS IN EXUDATIVE AGE–RELATED MACULAR DEGENERATION: The ARI2 Study
por: Blanco-Garavito, Rocio, et al.
Publicado: (2018)